Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD supranational laboratory network: First round of proficiency testing

International Journal of Tuberculosis and Lung Disease

Volumn 1, Issue 3, 1997, Pages 231-238

  Laszlo, A ^a   Rahman, M ^a   Raviglione, M ^b   Bustreo, F ^b  

^a LAB CENTRE FOR DISEASE CONTROL   (Canada)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Drug susceptibility testing; M. Tuberculosis; Quality assurance; Supranational Laboratory Network; WHO IUATLD

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ARTICLE; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; HEALTH CARE QUALITY; HEALTH SURVEY; HOSPITAL INFORMATION SYSTEM; HUMAN; LUNG TUBERCULOSIS; MICROBIOLOGICAL EXAMINATION; MYCOBACTERIUM TUBERCULOSIS; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

ANTITUBERCULAR AGENTS; CLINICAL LABORATORY INFORMATION SYSTEMS; DRUG THERAPY, COMBINATION; ETHAMBUTOL; HUMANS; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; QUALITY ASSURANCE, HEALTH CARE; RIFAMPIN; SENSITIVITY AND SPECIFICITY; STREPTOMYCIN; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; WORLD HEALTH ORGANIZATION;

EID: 0031151411     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Edlin B R, Tokars J I, Grieco M H, et al. An outbreak of multidrug resistance tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992; 326: 1514-1521.
2. Pearson M L, Jereb J A, Frieden T R, et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis: a risk to patients and health care workers. Ann Intern Med 1992; 117: 191-196.
3. Angarano G, Carbonara D, Costa D, Italian Tuberculosis Drug Resistance Study Group. Drug resistance of Mycobacterium tuberculosis strains isolated from HIV-infected Italian patients: preliminary report from a multicentric study. Microbiologica 1995; 18: 69-72.
4. De Beenhouwer H, Lhiang Z, Jannes G, et al. Rapid detection of rifampin resistance in sputum and biopsy specimens from tuberculosis patients by PCR. Tubercle Lung Dis 1995; 76: 425-430.
5. Laszlo A, de Kantor I N. A random sample survey of initial drug resistance among tuberculosis cases in Latin America. Bull World Health Organ 1994; 72: 603-610.
6. World Health Organization Tuberculosis Programme and International Union Against Tuberculosis and Lung Disease. Guidelines for surveillance of drug resistance in tuberculosis. Document WHO/TB/94.178, Geneva, 1994.
7. Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug sensitivity and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ 1969; 41: 21-43.
8. Public Health Mycobacteriology. A guide for the level III laboratory. 1985. P. T. Kent and G. P. Kubica. U.S. Department of Health and Human Services. Centers for Disease Control, Atlanta, Georgia 30333, pp. 159-184.
9. Siddiqi S H, Bactec TB System. Product and Procedure Manual. 1989. Becton Dickinson, Towson, MD, USA.
10. Medizinische Mikrobiologie Tuberkulosediagnostik. Teil 8: Empfindlichkeitsspufung von Tuberkulosebakterien gegen Chemotherapeutika DIN. 58943-8 September 1994.
11. Toman K. Sensitivity, specificity and predictive value of diagnostic tests. Bull Int Union Tuberc 1981; 56: 18-28.
12. Blyth C R. Approximate binomial confidence limits. JASA 1986; 81: 843-855.
13. Clarridge and Rambo ASM News 1995; 61: 271-272.
14. Ridderhof J, Good R, Muir H, et al. Assessing the performance of drug susceptibility testing for Mycobacterium tuberculosis in U.S. laboratories. TB notes Spring/Summer. CDC 1995 pp. 11-12.
15. Fox W. Philip Elman lecture. The modern management and therapy of pulmonary tuberculosis. Proc R Soc Med 1977; 70: 4-15.